Foghorn therapeutics appoints lynne parshall to its board of directors

Cambridge, mass., aug. 17, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced the election of b. lynne parshall, esq., to its board of directors and appointment as chair of the audit committee.
FHTX Ratings Summary
FHTX Quant Ranking